The Denton facility expands Novartis’ U.S. radioligand therapy manufacturing network as part of the company’s broader $23 billion domestic investment plan.
The collaboration will support lentiviral vector manufacturing and analytical testing for rare inherited disease programs under development at the National Institutes of Health.
Join this session to learn how life sciences manufacturers are leveraging advanced flow measurement insights to improve reliability, maintain compliance, and deliver confidence across every batch, cleaning cycle, and critical process.
